Maxim Group analyst Jason McCarthy has maintained their bullish stance on ATNM stock, giving a Buy rating yesterday.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors that highlight Actinium Pharmaceuticals’ promising advancements in their radiopharmaceutical pipeline. The company is actively progressing its Actimab-A programs in acute myeloid leukemia (AML), with a pivotal Phase 2/3 study expected to commence by the end of 2025. Additionally, initial data from a Phase 1 triplet study in frontline AML is anticipated in the second half of 2025, which could provide significant insights into the treatment’s efficacy.
Furthermore, Actinium is making strides in solid tumor treatments, with Phase 1 trials for Actimab-A in combination with Keytruda or Opdivo expected to yield proof-of-concept data by year-end 2025. The company’s preclinical data for ATNM-400 in prostate cancer has shown promising results, outperforming existing treatments and demonstrating robust efficacy in resistant models. These developments, along with ongoing trials and collaborations, underpin McCarthy’s optimistic outlook and Buy rating for Actinium Pharmaceuticals.
McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Capricor Therapeutics, and OS Therapies Incorporated. According to TipRanks, McCarthy has an average return of -21.3% and a 26.76% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.